Isolation and identification of process impurities in crude valsartan by HPLC, mass spectrometry, and nuclear magnetic resonance spectroscopy

Journal of Liquid Chromatography and Related Technologies

Volumn 29, Issue 4, 2006, Pages 553-568

  Nie, Jing ^a   Xiang, Bingren ^a   Feng, Yuqi ^b   Wang, Danhua ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c Zhejiang Huahai Pharmaceutical Co Ltd   (China)

Author keywords

Degradation; Electrospray ionization mass spectrometry; Impurities; Liquid chromatography; Nuclear magnetic resonance spectroscopy; Valsartan

Indexed keywords

DEGRADATION; IMPURITIES; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ELECTROSPRAY IONIZATION MASS SPECTROMETRY; VALSARTAN;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

N VALERYL N [[2' (1 METHYLTETRAZOL 5 YL)BIPHENYL 4 YL]METHYL]VALINE; UNCLASSIFIED DRUG; VALINE; VALSARTAN;

ANALYTIC METHOD; ARTICLE; CHEMICAL REACTION; DRUG IMPURITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION PROCEDURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCESS MONITORING; REACTION ANALYSIS;

EID: 33644638438     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070500479179     Document Type: Article

References (17)

1. International Conference on the Harmonization of the Technical Requirements for Registration of Pharmaceuticals for Human Use-Impurities in New Drug SubstancesICH Steering Committee, 1995, March 30.
2. Franolic, J.D.; Lehr, G.J.; Barry, T.L.; Petzinger, G. Isolation of a 2:1 hydrochlorothiazide-formaldehyde adduct impurity in hydrochlorothiazide drug substance by preparative chromatography and characterization by electrospray ionization LC-MS. J. Pharm. Biomed. Anal. 2001, 26, 651.
3. Lehr, G.J.; Barry, T.L.; Petzinger, G.; Hanna, G.M.; Zito, S.W. Isolation and identification of process impurities in trimethoprim drug substance by high-performance liquid chromatography, atmospheric pressure chemical ionization liquid chromatography: mass spectrometry and nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 1999, 19, 373.
4. Alsante, K.M.; Boutros, P.; Couturier, M.A.; Friedmann, R.C.; Harwood, J.W.; Horan, G.J.; Jensen, A.J.; Liu, Q.; Lohr, L.L.; Morris, R.; Raggon, J.W.; Reid, G.L.; Santafianos, D.P.; Sharp, T.R.; Tucker, J.L.; Wilcox, G.E. Pharmaceutical impurity identification: a case study using a multidisciplinary approach. J. Pharm. Sci. 2004, 93, 2296.
5. Bühlmayer, P.; Furet, P.; Criscione, L.; Gasparo, M.; Whitebread, S.; Schmidlin, T.; Lsmnann, R.; Wood, J. Valsartan, a potent, orally active angiotention II antagolist developed from the structurally new amino acid series. Bioorg. Med. Chem. Lett. 1994, 4, 29.
6. Cocolas, G.H.; Delgado, J.N.; Remers, W.A., Eds. Textbook of Organic Medicinal and Pharmaceutical Chemistry, 10th Ed.; Lippincott-Raven: Philadelphia, New York, 1998; 603.
7. Wexler, W.A.; Greenlee, W.J.; Irvin, J.D.; Goldberg, M.R.; Prendergast, K.; Smith, R.D.; Timmermans, P.B.M.W.M. Nonpeptide angiotensin II receptor antagonists: The next generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625.
8. Tatar, S.; Saǧlik, S. Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J. Pharm. Biomed. Anal. 2002, 30, 371.
9. Şatana, E.; Altinay, Ş.; Göǧer, N.G.; Özkan, S.A.; Şentürk, Z. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J. Pharm. Biomed. Anal. 2001, 25, 1009.
10. Cagigal, E.; González, L.; Alonso, R.M.; Jiménez, R.M. Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine. Talanta 2001, 54, 1121.
11. González, L.; López, J.A.; Alonso, R.M.; Jiménez, R.M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr. A 2002, 949, 49.
12. Daneshtalab, N.; Lewanczuk, R.Z.; Jamali, F. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J.Chromatogr. B 2002, 766, 345.
13. Hillaert, S.; Bossche, W.V. Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis. J. Pharm. Biomed. Anal. 2003, 31, 329.
14. Hillaert, S.; Bossche, W.V. Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-II-receptor antagonists. J. Chromatogr. A 2002, 979, 323.
15. Hillaert, S.; De Beer, T.R.M.; De Beer, J.O.; Bossche, W.V. Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists. J. Chromatogr. A 2003, 984, 135.
16. Snyder, L.R.; Kirkland, J.J.; Glajch, J.L. Practical HPLC Method Development, 2nd Ed; John Wiley & Sons, Inc.: New York, 1997.
17. Zhao, Z.; Wang, Q.; Tsai, E.W.; Qin, X.Ip.D. Identification of losartan degradates in stressed tablets by LC-MS and LC-MS:MS. J. Pharm. Biomed. Anal. 1999, 20, 129.